Wall Street analyst estimates for Inventiva S.A. (IVA): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-09-25 | $-0.20 | ||
| 2026-03-30 | $-1.07 | $-0.23 | -365.2% |
| 2025-09-25 | $-1.89 | $-0.41 | -361.7% |
| 2025-03-26 | $-2.19 | $-0.44 | -398.1% |
| 2024-09-25 | $-1.01 | $-0.56 | -81.1% |
| 2024-03-27 | $-1.25 | $-0.40 | -211.7% |
| 2023-09-28 | $-1.43 | $-1.27 | -13.1% |
| 2023-03-29 | $-0.64 | $-0.57 | -11.9% |
Valuation Ratios
| Price / Book | -71.60 |
| EV / EBITDA | -5.72 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.4M | $6.5M | $3.2M | $7.0M | $372000 | $4.2M | $12.2M | $17.5M | $9.2M | $4.5M |
| Cost of Revenue | $1.5M | $1.2M | $967000 | 0 | $846000 | $1.0M | $995000 | -$23000 | $3.9M | $2.8M |
| Gross Profit | $8.0M | $5.3M | $2.2M | $7.0M | $4.4M | $4.2M | $17.1M | $17.5M | $9.2M | $1.5M |
| Research & Development | $22.1M | $26.7M | $31.6M | $33.8M | $23.7M | $48.5M | $60.5M | $110.0M | $90.9M | $83.6M |
| Selling, General & Admin | $3.3M | $4.1M | $4.5M | $4.5M | $9.1M | $11.5M | $15.5M | $15.6M | $17.1M | $53.9M |
| Operating Expenses | $21.5M | $27.0M | $36.4M | $36.2M | $34.1M | $56.3M | $74.2M | $120.2M | $106.8M | $137.4M |
| Operating Income | -$13.0M | -$20.9M | -$33.3M | -$30.3M | -$29.7M | -$52.1M | -$57.1M | -$102.7M | -$97.6M | -$130.9M |
| EBITDA | -$11.1M | -$22.0M | -$32.0M | -$28.8M | -$31.8M | -$52.8M | -$56.3M | -$102.0M | -$166.5M | -$128.2M |
| Interest Expense | $7548 | $5316 | $243028 | $3000 | $66000 | $138000 | $707000 | $5.2M | $12.2M | $32.3M |
| Pre-tax Income | -$12.6M | -$20.6M | -$33.4M | -$30.2M | -$33.6M | -$49.3M | -$54.3M | -$109.8M | -$183.9M | -$342.3M |
| Income Tax | -$5.5M | -$3.4M | $253000 | 0 | 0 | $364000 | -$20000 | $607000 | $313000 | $22000 |
| Net Income | -$7.0M | -$17.2M | -$33.6M | -$30.2M | -$33.6M | -$49.6M | -$54.3M | -$110.4M | -$184.2M | -$340.2M |
| EPS | $-0.45 | $-1.11 | $-1.64 | $-1.28 | $-0.99 | $-1.27 | $-1.31 | $-2.43 | $-3.54 | $-1.82 |
| EPS (Diluted) | $-0.45 | $-1.11 | $-1.64 | $-1.28 | $-0.99 | $-1.27 | $-1.31 | $-2.43 | $-3.54 | $-1.82 |
| Shares Outstanding (Diluted) | $15.7M | $15.5M | $20.5M | $23.5M | $33.9M | $39.2M | $41.4M | $45.4M | $52.0M | $186.8M |
Price
| Price | $3.79 |
| Market Cap | $197M |
| Exchange | NASDAQ |
| Country | FR |
Related companies: AVTX · CRBU · ENTA · EPRX · GNFT · IVVD · NAUT
Explore sector: Healthcare · Biotechnology
More sections of IVA: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks